Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges

Scale-up remains one of the most critical unsolved challenges in iPSC-derived cell therapy. Despite strong clinical promise, most manufacturing processes today can only supply material for a very limited number of patients — a bottleneck that limits clinical progression and commercial viability across the field.

Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, today announced the launch of an internal program focused on scalable, GMP-compatible manufacturing of iPSC-derived beta cells for the treatment of Type 1 diabetes. The program is supported by a €12 million non-dilutive grant from Bpifrance.

The program is designed as a technology and process demonstrator, not a therapeutic development program. It pursues two distinct objectives:

• Process development: establish scalable, GMP-ready manufacturing processes for iPSC-derived cell therapies
• Analytics and quality: establish a robust characterization and release testing framework suited to iPSC-derived products.

The program is carried out in partnership with Human Cell Design, a French biotech and owner of EndoC-βH5® — a human beta cell line with functional characteristics closely resembling those of native pancreatic beta cells — and with the group of Prof. Raphaël Scharfmann (Institut Cochin, INSERM U1016, Université Paris Cité), one of the leading academic teams in human beta cell biology.

The initiative is driven by a clear market need. An increasing number of biotech and pharma companies developing iPSC-based therapies are encountering significant bottlenecks when transitioning from early-stage research to robust, GMP-compliant manufacturing. This program is Cell-Easy’s response: a concrete, risk-reduction platform for partners navigating this transition.

“iPSC-based programs are reaching a critical inflection point where scale-up can make or break clinical translation. We are building the manufacturing answers before our partners need them — with the biology expertise of best-in-class partners and the process and GMP rigor of an experienced CDMO.” Alexis Delbaere, CEO, Cell-Easy

Positioning Cell-Easy as a key iPSC manufacturing partner

This program reinforces Cell-Easy’s position as a manufacturing partner for biotech and pharma companies seeking to industrialize iPSC-derived cell therapies — from process development through GMP production.